Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236543274> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4236543274 abstract "Abstract Background: Recent genomic analyses revealed that druggable molecule targets were detectable in approximately 6% of patients with nasopharyngeal carcinoma (NPC). However, a dependency on dysregulated CDK4/6–cyclinD1 pathway signaling is an essential event in the pathogenesis of NPC. In this study, we aimed to evaluate the therapeutic efficacy of a specific CDK4/6 inhibitor, palbociclib, and its compatibility with other chemotherapeutic drugs for the treatment of NPC by using newly established xenograft models and cell lines derived from primary, recurrent, and metastatic NPC. Methods: We evaluated the efficacies of palbociclib monotherapy and concurrent treatment with palbociclib and cisplatin or suberanilohydroxamic acid (SAHA) in NPC cell lines and xenograft models. RNA sequencing was then used to profile the drug response–related pathways. Palbociclib-resistant NPC cell lines were established to determine the potential use of cisplatin as a second-line treatment after the development of palbociclib resistance. We further examined the efficacy of palbociclib treatment against cisplatin-resistant NPC cells. Results: In NPC cells, palbociclib monotherapy was confirmed to induce cell cycle arrest in the G1 phase in vitro . Palbociclib monotherapy also had significant inhibitory effects in all six tested NPC tumor models in vivo , as indicated by substantial reductions in the total tumor volumes and in Ki-67 proliferation marker expression. In NPC cells, concurrent palbociclib treatment mitigated the cytotoxic effect of cisplatin in vitro . Notably, concurrent treatment with palbociclib and SAHA synergistically promoted NPC cell death both in vitro and in vivo . This combination also further inhibited tumor growth by inducing autophagy-associated cell death. NPC cell lines with induced palbociclib or cisplatin resistance remained sensitive to treatment with cisplatin or palbociclib, respectively. Conclusions: Our study findings provide essential support for the use of palbociclib as an alternative therapy for NPC and increase awareness of the effective timing of palbociclib administration with other chemotherapeutic drugs. Our results provide a foundation for the design of first-in-human clinical trials of palbociclib regimens in patients with NPC." @default.
- W4236543274 created "2022-05-12" @default.
- W4236543274 creator A5010677692 @default.
- W4236543274 creator A5012341615 @default.
- W4236543274 creator A5012737253 @default.
- W4236543274 creator A5016090230 @default.
- W4236543274 creator A5020473726 @default.
- W4236543274 creator A5022526821 @default.
- W4236543274 creator A5025956851 @default.
- W4236543274 creator A5036659332 @default.
- W4236543274 creator A5061460834 @default.
- W4236543274 creator A5065914607 @default.
- W4236543274 creator A5070461179 @default.
- W4236543274 creator A5070808098 @default.
- W4236543274 creator A5072149610 @default.
- W4236543274 creator A5075553656 @default.
- W4236543274 creator A5090606171 @default.
- W4236543274 date "2020-10-30" @default.
- W4236543274 modified "2023-10-18" @default.
- W4236543274 title "Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma" @default.
- W4236543274 doi "https://doi.org/10.21203/rs.3.rs-36929/v2" @default.
- W4236543274 hasPublicationYear "2020" @default.
- W4236543274 type Work @default.
- W4236543274 citedByCount "0" @default.
- W4236543274 crossrefType "posted-content" @default.
- W4236543274 hasAuthorship W4236543274A5010677692 @default.
- W4236543274 hasAuthorship W4236543274A5012341615 @default.
- W4236543274 hasAuthorship W4236543274A5012737253 @default.
- W4236543274 hasAuthorship W4236543274A5016090230 @default.
- W4236543274 hasAuthorship W4236543274A5020473726 @default.
- W4236543274 hasAuthorship W4236543274A5022526821 @default.
- W4236543274 hasAuthorship W4236543274A5025956851 @default.
- W4236543274 hasAuthorship W4236543274A5036659332 @default.
- W4236543274 hasAuthorship W4236543274A5061460834 @default.
- W4236543274 hasAuthorship W4236543274A5065914607 @default.
- W4236543274 hasAuthorship W4236543274A5070461179 @default.
- W4236543274 hasAuthorship W4236543274A5070808098 @default.
- W4236543274 hasAuthorship W4236543274A5072149610 @default.
- W4236543274 hasAuthorship W4236543274A5075553656 @default.
- W4236543274 hasAuthorship W4236543274A5090606171 @default.
- W4236543274 hasBestOaLocation W42365432741 @default.
- W4236543274 hasConcept C105696609 @default.
- W4236543274 hasConcept C121608353 @default.
- W4236543274 hasConcept C126322002 @default.
- W4236543274 hasConcept C143998085 @default.
- W4236543274 hasConcept C150903083 @default.
- W4236543274 hasConcept C207001950 @default.
- W4236543274 hasConcept C2775930923 @default.
- W4236543274 hasConcept C2776694085 @default.
- W4236543274 hasConcept C2778239845 @default.
- W4236543274 hasConcept C2778997737 @default.
- W4236543274 hasConcept C2779744173 @default.
- W4236543274 hasConcept C29537977 @default.
- W4236543274 hasConcept C502942594 @default.
- W4236543274 hasConcept C509974204 @default.
- W4236543274 hasConcept C530470458 @default.
- W4236543274 hasConcept C71924100 @default.
- W4236543274 hasConcept C86803240 @default.
- W4236543274 hasConcept C98274493 @default.
- W4236543274 hasConceptScore W4236543274C105696609 @default.
- W4236543274 hasConceptScore W4236543274C121608353 @default.
- W4236543274 hasConceptScore W4236543274C126322002 @default.
- W4236543274 hasConceptScore W4236543274C143998085 @default.
- W4236543274 hasConceptScore W4236543274C150903083 @default.
- W4236543274 hasConceptScore W4236543274C207001950 @default.
- W4236543274 hasConceptScore W4236543274C2775930923 @default.
- W4236543274 hasConceptScore W4236543274C2776694085 @default.
- W4236543274 hasConceptScore W4236543274C2778239845 @default.
- W4236543274 hasConceptScore W4236543274C2778997737 @default.
- W4236543274 hasConceptScore W4236543274C2779744173 @default.
- W4236543274 hasConceptScore W4236543274C29537977 @default.
- W4236543274 hasConceptScore W4236543274C502942594 @default.
- W4236543274 hasConceptScore W4236543274C509974204 @default.
- W4236543274 hasConceptScore W4236543274C530470458 @default.
- W4236543274 hasConceptScore W4236543274C71924100 @default.
- W4236543274 hasConceptScore W4236543274C86803240 @default.
- W4236543274 hasConceptScore W4236543274C98274493 @default.
- W4236543274 hasLocation W42365432741 @default.
- W4236543274 hasLocation W42365432742 @default.
- W4236543274 hasLocation W42365432743 @default.
- W4236543274 hasOpenAccess W4236543274 @default.
- W4236543274 hasPrimaryLocation W42365432741 @default.
- W4236543274 hasRelatedWork W1948889165 @default.
- W4236543274 hasRelatedWork W2065693646 @default.
- W4236543274 hasRelatedWork W2078648913 @default.
- W4236543274 hasRelatedWork W2145657367 @default.
- W4236543274 hasRelatedWork W2170580929 @default.
- W4236543274 hasRelatedWork W2356421972 @default.
- W4236543274 hasRelatedWork W2357032622 @default.
- W4236543274 hasRelatedWork W2996719003 @default.
- W4236543274 hasRelatedWork W3140901227 @default.
- W4236543274 hasRelatedWork W4205782931 @default.
- W4236543274 isParatext "false" @default.
- W4236543274 isRetracted "false" @default.
- W4236543274 workType "article" @default.